News and Trends 4 Aug 2022 F2G to push anti-fungal agent with new $70M funding F2G Ltd, a clinical-stage biopharma company focused on therapies to treat life-threatening rare fungal infections with a high unmet medical need, has announced $70 million of financing. This was co-led by new investors Forbion and Sofinnova Partners, with participation from existing investors, Novo Holdings, Morningside Ventures, Cowen Healthcare Investments and Advent Life Sciences. Nanna Lüneborg […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 New breast cancer treatment receives funding Researchers at Queen’s University Belfast in Northern Ireland have received funding from Breast Cancer Now to search for new treatments inspired by COVID-19 vaccine innovation. The research team will adapt lessons from the development of COVID-19 vaccines in the hunt for new treatments for an aggressive form of breast cancer. Niamh Buckley and Helen McCarthy […] August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 The eyes have it – Visiox Pharma closes $7M seed round Visiox Pharma, LLC, a privately-funded U.S. biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, has announced the closing of a $7 million seed round of financing. The raise was funded by the Founding Partners and a group of ophthalmic industry leaders. […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. “We are excited […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ track record in forming innovative biotech companies, and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Deciphering the molecular mechanisms of severe COVID-19 Researchers from Fujita Health University School of Medicine in Japan have been investigating COVID-19 to lead to therapeutic options against the severe form of the condition. Levels of proinflammatory cytokines are dramatically elevated in severe COVID-19 patients, the molecular mechanisms of which remain unclear. In a recent article in mBio, the researchers elucidated the role […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Chinese biotech Sironax closes $200M funding round Sironax, an emerging Chinese biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, has completed $200 million in series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 siRNA company Eleven Therapeutics seals $22M funding Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 MAIA Biotechnology raises $10M from public offering U.S. clinical stage company MAIA Biotechnology, Inc. has closed its initial public offering of 2,000,000 shares of the company’s common stock at a public offering price of $5.00 per share. The gross proceeds from the initial public offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. The company has granted […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 IDRx launches with $122M to treat cancer with precision combination therapies DRx, Inc., a clinical-stage biopharmaceutical company, launched today with a $122 million oversubscribed series A financing. The financing was led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Inspired by a few curative combination regimens in cancer and the successful drug cocktails engineered […] August 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 FDA gives ok to Krystal Biotech cystic fibrosis clinical trial U.S. company Krystal Biotech is set to start a clinical trial for cystic fibrosis after the United States Food and Drug Administration (FDA) accepted its investigational new drug (IND) application. The gene therapy company will be evaluating KB407, a modified HSV-1 vector carrying two copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene to […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Defence Therapeutics says AccuTOX kills cancer cells Defence Therapeutics Inc., a Canadian biopharma company specializing in immune-oncology vaccines and drug delivery technologies, says it has discovered a novel DNA damaging function triggered by one of its lead compounds AccuTOX, which effectively elicits cell death in cancer cells. Cancer can be generally described as a state of uncontrolled cell proliferation. This is mainly […] August 2, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email